Systems and methods for controlling renovascular perfusion

Abstract

Devices, systems and methods by which the real or apparent renovascular perfusion and intrarenal pressure may be selectively and controllably increased. By selectively and controllably increasing renovascular perfusion and interstitial hydrostatic pressure when the heart is unable to pump sufficient blood or when renal perfusion is suboptimal, the present invention reduces or reverses neurohormonal activation and fluid retention, and thereby minimizes their deleterious effects on the heart, vasculature, kidneys and other body systems.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS[0001]The present application is a continuation of U.S. patent application Ser. No. 10 / 453,678, filed Jun. 2, 2003, which is a divisional of U.S. patent application Ser. No. 09 / 702,089, filed Oct. 30, 2000, the full disclosure of which is incorporated herein by reference.BACKGROUND OF THE INVENTION[0002]The present invention generally relates to medical devices and methods of use for the treatment and / or management of cardiovascular and renal disorders. Specifically, the present invention relates to devices and methods for controlling renal perfusion in the renovascular system for the treatment and / or management of cardiovascular disorders such as hypertension and congestive heart failure, and renal disorders such as renal insufficiency and end stage renal disease.[0003]Cardiovascular disease is a major contributor to patient illness and mortality. It also is a primary driver of health care expenditure, costing more than $326 billion each year...

AI Technical Summary

Benefits of technology

The present invention provides devices, systems, and methods for increasing the perfusion and pressure in the kidneys and restoring or augmenting perfusion when the heart or kidneys are unable to pump sufficient blood or when renal perfusion is suboptimal. This invention reduces or reverses the negative effects of reduced perfusion and neurohormonal activation on the heart, vasculature, kidneys, and other body systems. The invention includes a blood perfusion modification device, a physiologic sensor, and a control system that can activate or deactivate the device based on the sensor signal. The control system can also use an algorithm to determine the appropriate control signal based on the sensor signal. The invention can be used to treat various clinical conditions such as congestive heart failure, hypertension, renal failure, and cardiovascular abnormalities.

Problems solved by technology

Cardiovascular disease is a major contributor to patient illness and mortality.

Hypertension is a leading cause of heart failure and stroke.

It is the primary cause of death in over 42,000 patients per year and is listed as a primary or contributing cause of death in over 200,000 patients per year in the U.S. Accordingly, hypertension is a serious health problem demanding significant research and development for the treatment thereof.

Hypertension occurs when the body's smaller blood vessels (arterioles) constrict, causing an increase in blood pressure.

Because the blood vessels constrict, the heart must work harder to maintain blood flow at the higher pressures.

Although the body may tolerate short periods of increased blood pressure, sustained hypertension may eventually result in damage to multiple body organs, including the kidneys, brain, eyes and other tissues, causing a variety of maladies associated therewith.

The elevated blood pressure may also damage the lining of the blood vessels, accelerating the process of atherosclerosis and increasing the likelihood that a blood clot may develop.

This could lead to a heart attack and / or stroke.

Sustained high blood pressure may eventually result in an enlarged and damaged heart (hypertrophy), which may lead to heart failure.

It is characterized by an inability of the heart to pump enough blood to meet the body's needs and results in fatigue, reduced exercise capacity and poor survival.

It has been reported that the cost of treating heart failure in the United States exceeds $20 billion annually.

Accordingly, heart failure is also a serious health problem demanding significant research and development for the treatment and / or management thereof.

Accordingly, ESRD is a major health problem demanding improved therapy and management.

Heart failure results in the activation of a number of body systems to compensate for the heart's inability to pump sufficient blood.

The cardiac, renal and vascular responses increase the workload of the heart, further accelerating myocardial damage and exacerbating the heart failure state.

Although each of these alternative approaches is beneficial in some ways, each of the therapies has its own disadvantages.

For example, drug therapy is often incompletely effective.

Some patients may be unresponsive (refractory) to medical therapy.

Drugs often have unwanted side effects and may need to be given in complex regimens.

These and other factors contribute to poor patient compliance with medical therapy.

Drug therapy may also be expensive, adding to the health care costs associated with these disorders.

Likewise, surgical approaches are very costly, may be associated with significant patient morbidity and mortality and may not alter the natural history of the disease.

Images